Literature DB >> 10891409

Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.

K M Lockridge1, M Chien, G A Dean, K Stefano Cole, R C Montelaro, P A Luciw, E E Sparger.   

Abstract

To determine whether live-attenuated feline immunodeficiency virus (FIV) proviral DNA will induce protective immunity, a plasmid clone constructed with a FIV provirus containing a deletion in the viral accessory gene vif (FIV-pPPR-Deltavif) was inoculated as proviral DNA into four cats by the intramuscular route. After 43 weeks, these cats were boosted with the same proviral plasmid. Analysis of peripheral blood mononuclear cells at several time points after the primary and booster inoculations revealed no detectable virus or proviral DNA. At 6 weeks after the booster, immunized cats and additional naive control cats were challenged with a cell-free preparation of the infectious biological isolate FIV-PPR by the intraperitoneal route. Virus was detected after challenge in unvaccinated control cats but not in any of the FIV-pPPR-Deltavif-immunized cats. Both FIV Gag- and Env-specific cytotoxic T lymphocyte (CTL) activities were detected in peripheral blood cells of control cats after challenge infection, whereas only one of four cats immunized with FIV-pPPR-Deltavif DNA exhibited a measurable CTL response to Env following challenge. Although anti-Gag antibodies were not detected after both proviral DNA inoculation and challenge, anti-Env antibodies were found in FIV-pPPR-Deltavif-immunized cats after vaccination as well as after challenge. These findings indicate that inoculation with FIV-pPPR-Deltavif proviral DNA induced resistance to challenge with infectious FIV and that a vif deletion mutant may provide a relatively safe attenuated lentiviral vaccine. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891409     DOI: 10.1006/viro.2000.0395

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.

Authors:  J D Steckbeck; H J Grieser; T Sturgeon; R Taber; A Chow; J Bruno; M Murphy-Corb; R C Montelaro; K S Cole
Journal:  J Med Primatol       Date:  2006-08       Impact factor: 0.667

3.  Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.

Authors:  Jodi K Craigo; Feng Li; Jonathan D Steckbeck; Shannon Durkin; Laryssa Howe; Sheila J Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.

Authors:  Nathan C Gaddis; Elena Chertova; Ann M Sheehy; Louis E Henderson; Michael H Malim
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.

Authors:  Kun Luo; Bindong Liu; Zuoxiang Xiao; Yunkai Yu; Xianghui Yu; Robert Gorelick; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.

Authors:  Saipiroon Maksaereekul; Robert A Dubie; Xiaoying Shen; Hung Kieu; Gregg A Dean; Ellen E Sparger
Journal:  Vaccine       Date:  2009-04-17       Impact factor: 3.641

10.  Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine.

Authors:  Ellen E Sparger; Robert A Dubie; Barbara L Shacklett; Kelly S Cole; W L Chang; Paul A Luciw
Journal:  Virology       Date:  2008-02-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.